DARWIN PRECISIONS Chairman Kuo-Hsin Tsai is driving the company’s transformation by investing in technology R&D and establishing new ventures. This year, the Taichung Daya plant has been converted into a biomedical R&D and manufacturing hub, shifting its focus from panels to face masks. DARWIN’s subsidiary, Shine Biomedical Technology, inaugurated its new factory, aiming for a monthly output of 5 million face masks in 2026, while micro-needle business from MicroDoctor Biomedical is expected to start contributing to profits.

Previously, DARWIN’s Taichung Daya plant produced backlight modules and PMMA polymer pellets. With backlight production lines relocated overseas, only a small portion of electronic whiteboard and digital signage production remains. The two buildings at the Daya site have been repurposed into a biomedical R&D and manufacturing center: one building serves as MicroDoctor Biomedical’s micro-needle R&D facility, while the other houses Shine Biomedical’s R&D and production operations. With the new factory entering mass production, DARWIN expects its biomedical business to take off in 2026, projecting over 50% revenue growth from the new ventures.

Shine Biomedical is a joint venture between DARWIN and face mask and skincare OEM Meng Xiang Biotech. Trial operations began last year, with a cumulative production of 43 million face masks. General Manager Yu-Nan Lin, formerly at DARWIN, has applied production experience from panels and backlight modules to face mask manufacturing, creating fully automated lines for cutting, packaging, and filling face masks. AOI inspection has been introduced, reducing manpower by half and lowering microbial contamination risks. Lin outlined four operational targets for the new factory next year: first, to raise monthly production of face masks and skincare products to over 5 million pieces; second, to double hydrogel mask capacity; third, to begin mass production of micro-needle products, aiming for profitable contribution; and fourth, to leverage medical device manufacturing certification obtained this year to accelerate mass production and shipping next year.

Kuo-Hsin Tsai added that another wholly owned subsidiary, MicroDoctor Biomedical, leverages DARWIN’s past expertise in precision microstructure processing and opto-mechatronic integration from the panel industry to develop dissolvable micro-needle patches, micro-needle rollers, and composite micro-needle face masks. These products offer high skin compatibility and permeability, already applied in anti-wrinkle, spot-reducing, and eye-area repair medical aesthetics products, incorporating bioactive ingredients such as exosomes and plant stem cells. The company plans to further expand into regenerative medicine, with future applications extending to drug and vaccine delivery patches.

Resource: 達運新廠量產 明年生醫事業起飛